Ignite Creation Date:
2025-12-26 @ 5:18 PM
Ignite Modification Date:
2025-12-29 @ 1:00 AM
Study NCT ID:
NCT00877006
Status:
COMPLETED
Last Update Posted:
2018-02-05
First Post:
2009-04-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-04-30
Start Date Type:
None
Primary Completion Date:
2012-03-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-03-31
Completion Date Type:
ACTUAL
First Submit Date:
2009-04-03
First Submit QC Date:
None
Study First Post Date:
2009-04-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-03-25
Results First Submit QC Date:
None
Results First Post Date:
2014-04-28
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2013-08-20
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2018-01-08
Last Update Post Date:
2018-02-05
Last Update Post Date Type:
ACTUAL